GlobalData has released
its new Country report, PharmaPoint: Meningococcal Vaccines Spain Drug Forecast
and Market Analysis to 2022. Meningococcal disease is an acute infection caused
by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and
severity of symptoms makes prompt and effective diagnosis and treatment nearly
impossible. For these reasons the meningococcal disease space is dominated by
vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra
and Novartis Menveo, account for the vast majority of global sales, with the US
adolescent market being the key target segment. GlobalData expects growth in
the meningococcal vaccines market to be primarily driven by the launch of
serotype B vaccines, which address a critical unmet need in the treatment
landscape. Vaccines that better protect infants and/or provide a longer
duration of immunity also have an opportunity to seize market share during
2012-2022.
To
Read The Complete Report with TOC :-
GlobalData
predicts that relative patient share for the three MenC conjugate vaccines will
remain unchanged for the duration of the forecast period because Nuron Biotechs
Meningitec, Novartis Menjugate kit, and Baxters NeisVac-C possess nearly
identical clinical profiles and price points. The MenC conjugate patient share
is largely determined by prescriber preference in Spain and therefore is not
expected to change drastically during the forecast period. In addition,
GlobalData believes that an expected change in the booster administration age,
from two to 11 years of age, will not dramatically alter sales, although a
small coverage rate decrease associated with the older age group may occur
(MSSSI, 2013).
Scope
- Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Spain from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting Spain Meningococcal Vaccines market.
To Buy a Copy Of This Report:-
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in Spain
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
No comments:
Post a Comment